SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Key Takeaways SRPT stock rose nearly 2% as enrollment began in cohort 8 of the phase Ib ENDEAVOR study.Sarepta tests sirolimus regimen to reduce Elevidys-related liver risks in non-ambulatory DMD patients.SRPT targets 25 patients, studying dose timings to address safety concerns after prior liver-related deaths.Shares of Sarepta Therapeutics (SRPT) rose about 2% yesterday after it announced that screening and enrollment are underway in cohort 8 of the phase Ib ENDEAVOR study.This cohort is designed to impro ...